The potential role of blisibimod for the treatment of systemic lupus erythematosus

International Journal of Clinical Rheumatology

Volumn 9, Issue 2, 2014, Pages 121-134

  Scheinberg, Morton A ^a   Srinivasan, Dinesh ^b   Martin, Renee S ^b  

^a AACD   (Brazil)

^b Anthera Pharmaceuticals Inc   (United States)

Author keywords

B cell; BAFF; blisibimod; lupus; SLE

Indexed keywords

B CELL ACTIVATING FACTOR; BELIMUMAB; BLISIBIMOD; TABALUMAB;

AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; NAUSEA; NONHUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RHINOPHARYNGITIS; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84899888570     PISSN: 17584272     EISSN: 17584280     Source Type: Journal    
DOI: 10.2217/ijr.14.7     Document Type: Article

References (64)

1. Cathcart ES, Idelson BA, Scheinberg MA, Couser WG. Beneficial effects of methylprednisolone 'pulse' therapy in diffuse proliferative lupus nephritis. Lancet 1(7952), 163-166 (1976).
2. Lateef A, Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res. Ther. 14(Suppl. 4), S4 (2012).
3. Grech P, Khamashta M. Targeted therapies in systemic lupus erythematosus. Lupus 22(10), 978-986 (2013).
4. Hahn BH. Belimumab for systemic lupus erythematosus. N. Engl. J. Med. 368(16), 1528-1535 (2013).
5. Ramos-Casals M, Sanz I, Bosch X, Stone JH, Khamashta MA. B-cell-depleting therapy in systemic lupus erythematosus. Am. J. Med. 125(4), 327-336 (2012).
6. Merrill JT, Neuwelt CM, Wallace DJ et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, Phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62(1), 222-233 (2010).
7. Merrill J, Buyon J, Furie R et al. Assessment of flares in lupus patients enrolled in a Phase II/III study of rituximab (EXPLORER). Lupus 20(7), 709-716 (2011).
8. Díaz-Lagares C, Croca S, Sangle S et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun. Rev. 11(5), 357-364 (2012).
9. Scheinberg MA. Lupus clinical trials: medication failure or failure in study design. Rev. Bras Reum. 51(5), 410-411 (2011).
10. Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64(4), 1215-1226 (2012).
11. Kalled SL. The role of BAFF in immune function and implications for autoimmunity. Immunol. Rev. 204, 43-54 (2005).
12. Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 24(3), 203-215 (2013).
13. Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404(6781), 995-999 (2000).
14. Tomino Y, Suzuki S, Gohda T et al. Serum cystatin C may predict the prognostic stages of patients with IgA nephropathy prior to renal biopsy. J. Clin. Lab. Anal. 15(1), 25-29 (2001).
15. Zhang J, Roschke V, Baker KP et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. 166(1), 6-10 (2001).
16. Groom J, Kalled SL, Cutler AH et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J. Clin. Invest. 109(1), 59-68 (2002).
17. Kawasaki A, Tsuchiya N, Fukazawa T, Hashimoto H, Tokunaga K. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun. 3(7), 424-429 (2002).
18. Neusser MA, Lindenmeyer MT, Edenhofer I et al. Intrarenal production of B-cell survival factors in human lupus nephritis. Mod. Pathol. 24(1), 98-107 (2011).
19. Xin G, Shi W, Xu L-X, Su Y, Yan L-J, Li K-S. Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J. Nephrol. 26(4), 683-690 (2013).
20. Raje NS, Hohl RJ, Faber EA,Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma. Presented at: 2011 ASCO Annual Meeting. Chigago, IL, USA, 3-7 June 2011.
21. Neri P, Kumar S, Fulciniti MT et al. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin. Cancer Res. 13(19), 5903-5909 (2007).
22. Navarra S V, Guzmán RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, Phase III trial. Lancet 377(9767), 721-731 (2011).
23. Furie R, Petri M, Zamani O et al. A Phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63(12), 3918-3930 (2011).
24. Wallace DJ, Stohl W, Furie RA et al. A Phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61(9), 1168-1178 (2009).
25. Furie RA, Petri MA, Wallace DJ et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 61(9), 1143-1151 (2009).
26. Genovese MC, Lee E, Satterwhite J et al. A Phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis. 72(9), 1453-1460 (2013).
27. Genovese MC, Fleischmann RM, Greenwald M et al. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann. Rheum. Dis. 72(9), 1461-1468 (2013).
28. Genovese MC, Bojin S, Biagini IM et al. Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a Phase II, randomized, placebo-controlled trial. Arthritis Rheum. 65(4), 880-889 (2013).
29. Genovese MC, Silverman GJ, Emery P et al. Efficacy and safety of subcutaneous administration of tabalumab, an anti-B cell activating factor monoclonal antibody, in rheumatoid arthritis: results from a Phase 3 multicenter, randomized, double-blind study. Presented at: ACR/ARHP Annual Meeting. San Diego, CA, USA, 25-30 October 2013.
30. Gatto B. Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells. Curr. Opin. Investig. Drugs 9(11), 1216-1227 (2008).
31. Tak PP, Thurlings RM, Rossier C et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, Phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 58(1), 61-72 (2008).
32. Genovese MC, Kinnman N, de La Bourdonnaye G, Pena Rossi C, Tak PP. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a Phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum. 63(7), 1793-1803 (2011).
33. Ginzler EM, Wax S, Rajeswaran A et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res. Ther. 14(1), R33 (2012).
34. Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 64(11), 3660-3665 (2012).
35. Wofsy D, Gordon C, Licu D, Copt S, Pena Rossi C, Isenberg D. Pharmacodynamic effects of Atacicept in SLE patients: 52-week data from the APRIL-SLE trial. Presented at: Annual Conference of the European League Against Rheumatism Madrid, Spain, 12-15 June 2013.
36. Wallace DJ, Goldenberg DM. Epratuzumab for systemic lupus erythematosus. Lupus 22(4), 400-405 (2013).
37. Wallace DJ, Kalunian K, Petri MA et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a Phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann. Rheum. Dis. 73(1), 183-190 (2013).
38. Gordon C, Clowse M, Houssiau F et al. Epratuzumab maintains improvements in disease activity for over 2 years in patients with moderate-to-severe systemic lupus erythematosus: results from an open-label long-term extension study. Presented at: Annual conference of the European League Against Rheumatism Madrid, Spain, 12- 15 June 2013.
39. Merrill JT, Burgos-Vargas R, Westhovens R et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, Phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62(10), 3077-3087 (2010).
40. Zimmer R, Scherbarth HR, Rillo OL, Gomez-Reino JJ, Muller S. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled Phase IIb clinical trial. Ann. Rheum. Dis. 72(11), 1830-1835 (2013).
41. Wang B, Higgs BW, Chang L et al. Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-? receptor antibody. Clin. Pharmacol. Ther. 93(6), 483-492 (2013).
42. McBride JM, Jiang J, Abbas AR et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a Phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 64(11), 3666-3676 (2012).
43. Lauwerys BR, Hachulla E, Spertini F et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon ?-kinoid. Arthritis Rheum. 65(2), 447-456 (2013).
44. Xu Z, Bouman-Thio E, Comisar C et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br. J. Clin. Pharmacol. 72(2), 270-281 (2011).
45. Shimamoto G, Gegg C, Boone T, Quéva C. Peptibodies: a flexible alternative format to antibodies. MAbs 4(5), 586-591 (2012).
46. Hsu H, Khare SD, Lee F et al. A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease. Clin. Exp. Rheumatol. 30(2), 197-201 (2012).
47. FDA Pharmacology Review of Benlysta (2011). www.accessdata.fda.gov/ drugsatfda-docs/nda/2011/125370Orig1s000PharmR.pdf
48. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu. Rev. Immunol. 18, 739-766 (2000).
49. Suzuki T, Ishii-Watabe A, Tada M et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J. Immunol. 184(4), 1968-1976 (2010).
50. Mimura Y, Sondermann P, Ghirlando R et al. Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. J. Biol. Chem. 276(49), 45539-45547 (2001).
51. Jefferis R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol. Sci. 30(7), 356-362 (2009).
52. Stohl W, Merrill JT, Looney RJ et al. Phase 1a single- and Phase 1b multiple-dose studies of AMG 623 (an anti-BAFF peptibody) in systemic lupus erythematosus (SLE). Arthritis Rheum. 58, S565 (2008).
53. Furie RA, Scheinberg MA, Leon G et al. Blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus Erythematosus. Arthritis Rheum. 64(12), 4169 (2012).
54. Scheinberg MA, Leon G, Abud-Mendoza C for the PEARL-SC Study. Clinical experience in Latin America with blisibimod amongst subjects with active, moderate-to-severe systemic lupus erythematosus: data from the Phase 2b PEARL-SC study. 10th International Congress on SLE. Buenos Aires, Argentina, 18-21 April 2013.
55. Furie RA, Thomas M, Chu A, Martin RS, Hislop C, Scheinberg MA. Effects of blisibimod, an inhibitor of b cell activating factor, on serum immunoglobulins and infection risk in patients with systemic lupus erythematosus: observations from the placebo-controlled Pearl-SC and open-label extension studies. Presented at: ACR/ARHP Annual Meeting. San Diego, CA, USA, 28 October 2013.
56. Linnik MD, Hu JZ, Heilbrunn KR, Strand V, Hurley FL, Joh T. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum. 52(4), 1129-1137 (2005).
57. Dooley MA, Houssiau F, Aranow C et al. Effect of belimumab treatment on renal outcomes: results from the Phase 3 belimumab clinical trials in patients with SLE. Lupus 22(1), 63-72 (2013).
58. Petri M, Stohl W, Chatham W et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 58(8), 2453-2459 (2008).
59. Stohl W, Hiepe F, Thomas M et al. Belimumab, a BLyS-specific inhibitor, significantly reduced autoantibodies, normalized low complement, and reduced selected B-cell populations in patients with seropositive systemic lupus erythematosus (SLE): the Phase 3 BLISS studies. Presented at: ACR/ARHP Annual Meeting. Atlanta, GA, USA, 7-11 November 2010.
60. Stohl W, Hiepe F, Latinis KM et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 64(7), 2328-2337 (2012).
61. Cattran DC, Coppo R, Cook HT et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 76(5), 534-545 (2009).
62. Lefkowith JB, Kiehl M, Rubenstein J et al. Heterogeneity and clinical significance of glomerular-binding antibodies in systemic lupus erythematosus. J. Clin. Invest. 98(6), 1373-1380 (1996).
63. Golmia AP, Martin RS, Hislop C Scheinberg MA. Disappearance of cryoproteins in the sera of a patient with systemic lupus after treatment with Blisibimod a novel subcutaneous anti B cell therapy. Rheumatology doi:10.1093/rheumatology/ket361 (2013) (Epub ahead of print).
64. van Vollenhoven RF, Petri MA, Cervera R et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 71(8), 1343-1349 (2012).